- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.24 | OBIO stock touches 52-week low at $3.96 amid market challenges | 1 | Investing.com | ||
| 26.12.24 | Orchestra Biomed CEO David Hochman erwirbt Stammaktien im Wert von 18.640 US-Dollar | 3 | Investing.com Deutsch | ||
| 20.12.24 | Orchestra BioMed CFO Taylor Lawrence kauft Unternehmensaktien für 4.830 US-Dollar | 2 | Investing.com Deutsch | ||
| 09.12.24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting | 1 | GlobeNewswire (USA) | ||
| 14.11.24 | Orchestra BioMed GAAP EPS of -$0.41, revenue of $0.99M | 1 | Seeking Alpha | ||
| 12.11.24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update | 134 | GlobeNewswire (Europe) | NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies... ► Artikel lesen | |
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09.24 | Orchestra BioMed executive acquires shares worth over $47k | 1 | Investing.com | ||
| 11.09.24 | Orchestra BioMed executive sells over $73k in company stock | 2 | Investing.com | ||
| 11.09.24 | Orchestra BioMed director sells over $30k in company shares | 4 | Investing.com | ||
| 07.09.24 | Orchestra BioMed executive sells over $120k in company stock | 3 | Investing.com | ||
| 13.08.24 | Orchestra BioMed reports Q2 results | 1 | Seeking Alpha | ||
| 12.08.24 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08.24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update | 129 | GlobeNewswire (Europe) | NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies... ► Artikel lesen | |
| 12.08.24 | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05.24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update | 949 | GlobeNewswire (Europe) | Company hosting in-person R&D day event, focused on atrioventricular interval modulation ("AVIM") therapy, including the unmet need in hypertension, mechanism of action, clinical results and design... ► Artikel lesen | |
| 27.03.24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update | 161 | GlobeNewswire (Europe) | Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with... ► Artikel lesen | |
| 06.02.24 | PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit | 545 | Newsfile | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds" or the "Company"), a clinical-stage neuroscience company dedicated to the development... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,560 | -3,20 % | Qiagen zahlt Ende Januar 1,26 US-Dollar je Aktie aus | VENLO (dpa-AFX) - Der Diagnostikspezialist und Labordienstleister Qiagen hat Details zu seinem sogenannten synthetischen Aktienrückkauf in Höhe von rund 300 Millionen US-Dollar bekanntgegeben. Je 36... ► Artikel lesen | |
| TEMPUS AI | 52,42 | +3,84 % | Der neue KI-Star: Cathie Wood und Nancy Pelosi haben schon zugegriffen - Tempus AI wird zum Muss! | © Foto: Gorodenkoff / Stock.adobe.comAufgepasst Siri und Alexa! Olivia, die KI-gestützte Gesundheits-Concierge-App von Tempus AI, ist auf dem Weg. Allein ihre Ankündigung bescherte Tempus AI den besten... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 21,060 | +640,25 % | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 | ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid... ► Artikel lesen | |
| DISC MEDICINE | 57,40 | -2,01 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| BIONTECH | 116,00 | +4,79 % | Kaufempfehlung bekräftigt: BioNTech: Spannende Pipeline macht Hoffnung auf deutlichen Kursanstieg | © Foto: Julia Cebella - dpaDie Analysten von Berenberg Research sehen großes Potenzial in BioNTechs Onkologie-Pipeline und betonen, dass die bevorstehenden klinischen Auswertungen bis 2025 die Bewertung... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,585 | +1,27 % | Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday | ||
| EVOTEC | 7,910 | -1,12 % | Chartanalyse: Evotec-Aktie: Es wird schon wieder kritisch! | © Foto: Christian Charisius/dpa - dpa-BildfunkIn der Aktie von Evotec ist es vor kurzem zu einem Kaufsignal gekommen. Das hat bislang aber keine Wirkung entfalten können. Der Chartcheck!Hinter den Evotec-Aktionären... ► Artikel lesen | |
| VERVE THERAPEUTICS | 8,310 | +6,54 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
| MODERNA | 37,315 | +0,21 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| JANUX THERAPEUTICS | 43,930 | +9,14 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ABSCI | 3,990 | -0,87 % | Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside | ||
| SANA BIOTECHNOLOGY | 3,490 | -0,29 % | Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5% - Here's Why | ||
| ARCELLX | 65,41 | -1,74 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 35,570 | +1,56 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,590 | +0,83 % | Beam Therapeutics to present updated BEAM-101 trial data |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,38 % bei einem Aktienkurs von 5,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.
